Genomics Core Facility The goal of the Genomics Core Facility (GCF) is to make genomic analysis products and services widely available to UNC LCCC members at cost-effective prices. Services include: producing low-cost custom microarrays for model organisms;analysis of RNA quality;support of the use of Agilent and Affymetrix gene expression microarrays and aCGH and microRNA microarrays;RNAi screening services;assisting with experimental design and analyzing results;archiving of both Agilent and Affimetrix array data;providing web based pathway analysis software;and providing """"""""walk-up"""""""" quantitative PCR analysis. The Core adds value to the Center by making accessible complex and expensive DNA technologies to UNC LCCC members. Well-integrated genomics and bioinformatics groups interact with the microarray user to ensure robust data that is archived appropriately for future use. Highlights of research supported by the Core include: Jen Jen Yeh's profiling studies of gene expression in pancreatic cancers, Charles Perou's profiling of cancer gene expression and the effects of cancer therapeutics, and characterization of gene expression in a wide range of tumor types in support of the Cancer Genome Atlas (TCGA) Project. This year and next will see major changes. The Bioinformatics group, while remaining fully integrated, functionally is evolving into a separate core with multiple functions. The Genomics Core is also expanding to offer new techniques, including mapping of methylation sites, preparation of cDNA libraries from mRNA for mRNA-seq by the NexGen sequencing core;continuing development of an RNAi High-throughput Screening facility for functional genomics studies;and offering Nanostring technology for multiplex quantitative measurement of mRNA without amplification. Lastly, the Agilent and Affimetrix microarray components will be physically consolidated in newly renovated space with the DNA Sequencing, Mammalian Genotyping, and High Throughput (Next-Generation) Sequencing Facility. This will enable the cores to more fully integrate and flexibly service users. In 2009, the core was used by 91 investigators. Peer-review funded members accounted for 87% of total core use. Fifty-five Cancer Center members from eight programs used the core. CCSG funding of $167,411 is requested for 2010, representing 10% of the projected operating costs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594164
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$212,220
Indirect Cost
$66,183
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kolupaev, Oleg V; Dant, Trisha A; Bommiasamy, Hemamalini et al. (2018) Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. Blood Adv 2:2307-2319
Beckford Vera, Denis R; Smith, Christof C; Bixby, Lisa M et al. (2018) Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS One 13:e0193832
McLamarrah, Tiffany A; Buster, Daniel W; Galletta, Brian J et al. (2018) An ordered pattern of Ana2 phosphorylation by Plk4 is required for centriole assembly. J Cell Biol 217:1217-1231
Sanoff, Hanna K (2018) Best Evidence Supports Annual Surveillance for Resected Colorectal Cancer. JAMA 319:2083-2085
Chiou, Yi-Ying; Hu, Jinchuan; Sancar, Aziz et al. (2018) RNA polymerase II is released from the DNA template during transcription-coupled repair in mammalian cells. J Biol Chem 293:2476-2486
Kwo, Paul; Fried, Michael W; Reddy, K Rajender et al. (2018) Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. Hepatol Commun 2:354-363
Dunn, Julia L M; Kartchner, Laurel B; Gast, Karli et al. (2018) Mammalian target of rapamycin regulates a hyperresponsive state in pulmonary neutrophils late after burn injury. J Leukoc Biol 103:909-918
Xiao, Weidong; Gao, Guangping; Ling, Chen et al. (2018) Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates. Nat Med 24:699
Zhang, Xintao; He, Ting; Chai, Zheng et al. (2018) Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. Biomaterials 176:71-83
Wang, Sheng; Che, Tao; Levit, Anat et al. (2018) Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 555:269-273

Showing the most recent 10 out of 1525 publications